Figure 2. Patterns of Glucose Metabolism in β-Amyloid Peptide–Negative (Aβ−) and Neurodegeneration-Positive (N+) Noncarriers of APOE ε4 With Mild Cognitive Impairment Noncarriers Compared With Aβ−N+ Carriers of APOE ε4.

Brain surface images demonstrate the results of whole-brain fluorodeoxyglucose F 18–labeled (FDG) voxelwise analysis in Aβ−N+ noncarriers of APOE ε4 contrasted against Aβ−N+ carriers of APOE ε4. Red indicates clusters that met the significant cluster-level threshold of P < .05 corrected (voxelwise threshold P < .001 uncorrected, k = 260 voxels; eTable 1 in the Supplement). The blue regions of interest (ROIs) represent prespecified meta-ROIs. There were no regions in which APOE ε4− individuals showed lower glucose metabolism than did APOE ε4+ individuals (reverse contrasts in eFigure 2 in the Supplement).